Anita W. Asgar, MD, MSc, FACC
Section Chief, Interventional Cardiology
Medical Director, Structural Heart Program
Bluhm Cardiovascular Institute, Northwestern Medicine
Professor of Medicine
Northwestern University Feinberg School of Medicine
Chicago, Illinois
anita.asgar@nm.org
Disclosures: Consultant to Medtronic.

The management of severe aortic stenosis (AS) in women requires an understanding of how sex influences disease presentation, anatomy, procedural risk, and treatment outcomes. The essentials for appropriate transcatheter aortic valve replacement (TAVR) decision-making should then focus on three main areas: (1) diagnosis, (2) anatomic evaluation, and (3) treatment selection.

In practice, each step requires attention to differences in disease biology, cardiac and vascular anatomy, and procedural risk. Women are not simply smaller versions of men, and a strategy based on conventional risk scores alone may overlook important factors that influence treatment. The following considerations are particularly relevant to contemporary TAVR practice.

Dr. Asgar’s Three Keys for TAVR Decision-Making in Women

  • Recognize severe AS and intervene at the appropriate time.
  • Understand anatomy before selecting a valve.
  • Integrate the evidence for TAVR versus surgery into a lifetime management plan.

1. Diagnosis: Recognize severe AS and avoid delayed intervention. The first essential is an accurate assessment of disease severity and its clinical consequences. Women with AS often demonstrate smaller left ventricular cavities, more concentric remodeling, and preserved ejection fraction despite significant pressure overload. Symptoms may develop gradually and be attributed to age, reduced activity, or coexisting disease. Women tend to have less aortic valve calcification at a comparable hemodynamic severity of stenosis, with a relatively greater contribution from fibrosis. These differences matter when echocardiographic findings are discordant and may contribute to underrecognition of advanced disease.1,2

Echocardiography remains the foundation of AS assessment, but a small, calculated valve area and a low gradient require a careful review of flow, blood pressure, Doppler acquisition, and ventricular function. Paradoxical low-flow, low-gradient AS is not uncommon in women, and other modalities may be required to make the diagnosis. In selected patients, CT calcium scoring can provide important additional information. Sex-specific thresholds—approximately 1,300 Agatston units in women and 2,000 in men—can support a diagnosis of severe AS, although calcium scoring must be interpreted in the context of the complete clinical evaluation.3

The practical point is simple: Diagnosis of severe AS in women may be challenging and require careful symptom assessment, appropriate use of multimodality imaging, and timely heart team referral to achieve the best outcome.

2. Anatomic evaluation: Recognize how anatomy influences valve choice, procedural safety, and valve performance. Women more frequently have smaller aortic annuli, aortic root, and iliofemoral arteries. These characteristics shape preprocedural planning and the discussion of treatment options.

Small aortic annuli are especially important. They increase the likelihood of elevated residual gradients and prosthesis-patient mismatch, both of which may limit the hemodynamic benefit of valve replacement. In the SMART trial, 716 patients with small aortic annuli were randomized to self-expanding supra-annular or balloon-expandable TAVR; approximately 87% were women. At 1 year, the self-expanding platform was noninferior for the clinical composite endpoint of all-cause mortality, disabling stroke, or heart failure rehospitalization and superior for bioprosthetic valve dysfunction.4 These findings underscore the importance of valve hemodynamics in patients with small annuli, which should be taken into consideration as part of the valve selection process but to date have not translated into hard clinical outcomes at 2-year follow-up.

Valve selection also requires evaluation of coronary height, sinus diameters, and sinotubular junction dimensions, as well as leaflet and calcium distribution and anticipated future coronary access. These considerations are increasingly important as TAVR expands to patients with longer life expectancy. The initial valve may determine the feasibility and safety of subsequent interventions, including redo TAVR.

Peripheral access deserves the same attention as annular anatomy. Smaller vessel diameters, calcification, and tortuosity can increase vascular and bleeding complications. Detailed CT assessment, thoughtful selection of delivery systems, ultrasound-guided access, and a clear bailout strategy are essential. Historical studies described higher early vascular and bleeding complications in women despite favorable longer-term survival in some cohorts.1 Contemporary devices have reduced delivery profiles, but meticulous access planning remains fundamental. An excellent valve result is of limited value if accompanied by a major, potentially avoidable vascular complication.

3. Treatment selection: Choose the intervention that offers the best overall outcome for the individual patient. The RHEIA trial randomized women with severe symptomatic AS who were eligible for either transfemoral TAVR or surgical aortic valve replacement. At 1 year, the primary composite of death, stroke, or valve/procedure/heart failure–related rehospitalization occurred in 8.9% of patients assigned to TAVR and 15.6% assigned to surgery,5 providing important, randomized evidence supporting TAVR in appropriately selected women.

For many older women, the less invasive approach and faster recovery associated with TAVR may offer substantial benefit, particularly for those who are the primary caregivers for family members. In younger women, the decision is more nuanced. Considerations must focus on anticipated longevity, prosthesis durability, future coronary access, feasibility of redo TAVR, and the consequences of eventual valve failure. Surgery may be preferable when concomitant disease requires correction or when annular enlargement can meaningfully improve the lifetime strategy. Conversely, surgical recovery and procedural risks must be weighed carefully.

The heart team is integral in the treatment decision and communication of these trade-offs while considering the patient’s goals of care and priorities. The discussion must address survival and stroke as well as symptoms, independence, hospitalization, recovery, and future treatment options. Sex-related differences affect the entire pathway of care, from disease recognition and through treatment selection and outcomes.2 Our task as clinicians is to translate that knowledge into better decisions to ensure optimal outcomes for women with AS.

CONCLUSION

Three principles should guide TAVR decision-making in women: timely diagnosis of severe AS, understanding anatomy, and individualized treatment choices with a lifetime perspective. The objective is to ensure that each woman receives the right diagnosis and appropriate intervention at the right time, with a plan that delivers meaningful benefit today without compromising options tomorrow.

1. Pacheco C, Henri C, Forcillo J, Asgar A. Transcatheter aortic valve replacement for severe aortic stenosis in women: clinical characteristics and outcomes. Can J Cardiol. 2018;34:422-428. doi: 10.1016/j.cjca.2017.10.026

2. Hahn RT, Clavel MA, Mascherbauer J, et al. Sex-related factors in valvular heart disease: JACC Focus Seminar 5/7. J Am Coll Cardiol. 2022;79:1506-1518. doi: 10.1016/j.jacc.2021.08.081

3. Otto CM, Nishimura RA, Bonow RO, et al. 2020 ACC/AHA guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol. 2021;77:e25-e197. doi: 10.1016/j.jacc.2020.11.018

4. Herrmann HC, Mehran R, Blackman DJ, et al. Self-expanding or balloon-expandable TAVR in patients with a small aortic annulus. N Engl J Med. 2024;390:1959-1971. doi: 10.1056/NEJMoa2312573

5. Tchétché D, Pibarot P, Bax JJ, et al. Transcatheter vs. surgical aortic valve replacement in women: the RHEIA trial. Eur Heart J. 2025;46:2079-2088. doi: 10.1093/eurheartj/ehaf133


Ranya Sweis, MD, MS, FACC, FSCAI
Interventional Cardiologist
Northwestern Memorial Hospital
Clinical Practice Director, Cardiology Outpatient Clinic
Bluhm Cardiovascular Institute, Northwestern Medicine
Professor of Medicine
Northwestern University Feinberg School of Medicine
Chicago, Illinois
rsweis@nm.org
Disclosures: Course faculty for Edwards and Medtronic; research trial participant for Edwards, Medtronic, and Abbott.

1. Female patients with AS are underdiagnosed, undertreated, and underrepresented for cardiovascular disease in general and for AS specifically. Cardiovascular disease, including valvular disease, is the leading cause of death in women in the United States. However, due to variations in their symptoms and severity, women perceive their disease as less severe that it is, often present later in their disease process, and are less likely to undergo appropriate testing, and when they do have the studies, they are typically conducted later than in men. This results in decreased likelihood of early diagnosis and timely referral for treatment and contributes to the observed lower treatment rates in women.1 We also know that valvular disease can be more fibrocalcific and less calcified in women, so even when studies are obtained, severity is often underestimated.2 As a result, it is essential to have a high index of suspicion regarding valvular disease in women, understanding that their presentation and severity are different from those of men. Finally, women have been underrepresented in clinical trials. This limits the generalizability of their results to women and leaves gaps in evidence-based care for women.3

2. Women have smaller annuli, which has implications in terms of treatment selection and lifetime management. There is a higher risk of prosthesis-patient mismatch in women, particularly if an undersized valve is selected, so it is important to use the largest valve possible for the patient’s anatomy.4,5 This is especially critical in younger patients who may need additional valvular interventions in their lifetime, as the initial treatment decision must preserve future options to the degree possible without compromising long-term outcomes. Although women have higher complication rates with surgery, surgical valve replacement with aortic root enlargement may be more appropriate for some women with smaller annuli, especially in light of lifetime management of their AS.

3. Recognize that women have higher rates of bleeding and vascular injury during TAVR than men. This may be due to smaller access vessel anatomy, highlighting the importance of careful selection of patients, devices, and access sites. Bleeding avoidance strategies are essential in all patients, but they should be particularly considered in women due to their higher risk.6 

Dr. Sweis’s Three Keys for TAVR Decision-Making in Women

  • Female patients with AS are underdiagnosed, undertreated, and underrepresented.
  • Women have smaller annuli, which has implications for treatment selection and lifetime management.
  • Women have higher rates of bleeding and vascular injury during TAVR.

1. Lowenstern A, Sheridan P, Wang TY, et al. Sex disparities in patients with symptomatic severe aortic stenosis. Am Heart J. 2021;237:116-126. doi: 10.1016/j.ahj.2021.01.021

2. Iribarren AC, AlBadri A, Wei J, et al. Sex differences in aortic stenosis: Identification of knowledge gaps for sex-specific personalized medicine. Am Heart J Plus. 2022;21:100197. doi: 10.1016/j.ahjo.2022.100197

3. Rivera FB, Magalong JV, Bantayan NRB, et al. Participation of women in cardiovascular trials from 2017 to 2023: a systematic review. JAMA Netw Open. 2025;8:e2529104. Published correction appears in JAMA Netw Open. 2025;8:e2540119. doi: 10.1001/jamanetworkopen.2025.29104

4. Panoulas VF, Chandrasekhar J, Busi G, et al; WIN-TAVI Investigators. Prevalence, predictors, and outcomes of patient prosthesis mismatch in women undergoing TAVI for severe aortic stenosis: insights from the WIN-TAVI registry. Catheter Cardiovasc Interv. 2021;97:516-526. doi: 10.1002/ccd.29227

5. Sá MP, Jacquemyn X, Van den Eynde J, et al. Impact of prosthesis-patient mismatch after transcatheter aortic valve replacement: meta-analysis of Kaplan-Meier-derived individual patient data. JACC Cardiovasc Imaging. 2023;16:298-310. doi: 10.1016/j.jcmg.2022.07.013

6. O'Connor SA, Morice MC, Gilard M, et al. Revisiting sex equality with transcatheter aortic valve replacement outcomes: a collaborative, patient-level meta-analysis of 11,310 patients. J Am Coll Cardiol. 2015;66:221-228. doi: 10.1016/j.jacc.2015.05.024